Quick Answer
Celldex Therapeutics, Inc. reported Cash and Equivalents of $28.87 million for fiscal year 2025.
Celldex Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $28.87M | +1.8% |
| 2024 | $28.36M | -18.6% |
| 2023 | $34.81M | +18.3% |
| 2022 | $29.43M | -24.8% |
| 2021 | $39.14M | -10.7% |
| 2020 | $43.84M | +290.3% |
| 2019 | $11.23M | -53.8% |
| 2018 | $24.31M | -39.7% |
| 2017 | $40.29M | -5.1% |
| 2016 | $42.46M | -41.1% |
| 2015 | $72.11M | +157.3% |
| 2014 | $28.02M | -83.5% |
| 2013 | $169.40M | +580.4% |
| 2012 | $24.90M | +109.2% |
| 2011 | $11.90M | -44.1% |
| 2010 | $21.29M | -62.7% |
| 2009 | $57.00M | +28.8% |
| 2008 | $44.26M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $36.04M | -1.0% | +56.4% |
| June 30, 2025 | $23.04M | -46.1% | +34.5% |
| March 31, 2025 | $17.14M | -85.1% | -39.6% |
| December 31, 2024 | $28.36M | -18.6% | -22.1% |
| September 30, 2024 | $36.40M | +72.2% | -14.8% |
| June 30, 2024 | $42.74M | +51.4% | -62.9% |
| March 31, 2024 | $115.08M | +112.6% | +230.5% |
| December 31, 2023 | $34.81M | +18.3% | +64.7% |
- Celldex Therapeutics, Inc. showed an increase of +1.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Celldex Therapeutics, Inc.’s cash and equivalents has declined by 34.8% (from $44.26 million to $28.87 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: